EC Number   |
Inhibitors |
Structure |
|---|
   2.3.2.31 | methyl (2E)-4-[(2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carbonyl)amino]but-2-enoate |
labels RNF31 with proteome-wide selectivity and effectively inhibits linear polyubiquitin chain formation in vitro and in cells |
   |
| 2.3.2.31 | methyl (2E)-4-[(2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carbonyl)amino]but-2-enoate |
compound labels RNF31 RBR at the active site cysteine residue C885 in a time- and concentration-dependent manner. It effectively penetrates mammalian cells to inhibit RNF31 and NF-kappaB activation |
|
| 2.3.2.31 | more |
single-domain antibodies can modulate the activity of the E3 ligase HOIP and facilitate crystallization of its catalytic RBR domain. Single domain antibodies may inhibit most, if not all, ubiquitin linear chain formation with both E2 enzymes UbcH5C and UbcH7 equally, one group of antibodies has a small effect on the observed activity with UbcH5C, but drastically slows down linear chain formation with UbcH7 |
|
